Transcriptomic analysis of AD patient biopsies has shown enrichment for type 2 immune pathways, the importance of which is highlighted by the efficacy of dupilumab, an IL-4Rα antibody that inhibits IL-4 and IL-13 signaling in AD patients (Simpson et al., 2016). The gene discussed is IL13; the disease is Alzheimer disease.